)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Dermapharm (DMP) investor relations material
Dermapharm Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary26 Aug, 2025
Executive summary
Stable business in H1 2025 with revenue of €574.5m, down 0.7% year-over-year, mainly due to portfolio streamlining and reorganisation in certain segments; strong organic growth in high-margin branded pharmaceuticals and international business nearly offset declines in vaccine and parallel import businesses.
Adjusted EBITDA declined by 3.3% to €148.0m, with margin at 25.8% (down from 26.4%), mainly due to lower vaccine business.
Net profit/EAT for H1 2025 was €54.1m, down from €59.9m in H1 2024, impacted by lower exceptional income and higher interest expenses.
Portfolio optimization and restructuring, particularly at Arkopharma and axicorp, improved margins and operational efficiency.
The company maintained a strong position in branded pharmaceuticals, with international growth and product launches supporting performance.
Financial highlights
Total revenue for H1 2025 was €574.5m, down 0.7% year-over-year, as growth in branded pharmaceuticals and other healthcare nearly compensated for declines in vaccine and parallel import businesses.
Adjusted EBITDA decreased by 3.3% to €148.0m; reported EBITDA was €144.9m (down 1.4% year-over-year), with margin at 25.2%.
Earnings after tax (EAT) fell 9.7% to €54.1m; EBT margin at 14.3% for H1 2025, down from 15.7% in H1 2024.
Free cash flow improved to €50.9m (from €40.5m), and net cash flow from operating activities rose to €70.1m.
Total assets increased to €2,135.5m, while equity decreased slightly to €605.5m, with an equity ratio of 28.4%.
Outlook and guidance
Management confirms full-year 2025 guidance: revenues of €1,160m–1,200m and adjusted EBITDA of €322m–332m.
Branded pharmaceuticals expected to drive growth, with recovery anticipated in other healthcare products and parallel import business in H2 2025.
H1 2025 performance is in line with budget and provides a solid foundation for the second half.
Outlook subject to risks from regulatory changes, geopolitical tensions, and raw material price volatility.
Quantify pandemic preparedness program impact
Arkopharma reorg: H1 impact and H2 outlook
Why was currency risk upgraded to medium?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Dermapharm earnings date
Q3 202513 Nov, 2025
Next Dermapharm earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Dermapharm Holding SE is a Germany-based pharmaceutical company specializing in the development, production, and marketing of branded prescription and over-the-counter (OTC) medicines, dietary supplements, and medical devices. The company focuses on niche markets, offering a diverse portfolio of products across therapeutic areas such as dermatology, allergy, and pain management. Dermapharm also provides contract manufacturing services to third-party pharmaceutical companies. The company is headquartered in Grünwald, Germany, and its shares are listed on the Frankfurt Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage